|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
6
|
|
pubmed:dateCreated |
2006-2-7
|
|
pubmed:abstractText |
Patients with relapsed diffuse large B-cell lymphoma (DLBCL) who are either not suitable for stem cell transplantation or suffer from relapsed disease after standard second-line chemotherapy face a dismal prognosis. Most of them have a reduced performance status and do not tolerate intensive chemotherapy.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal,
http://linkedlifedata.com/resource/pubmed/chemical/Antibodies, Monoclonal...,
http://linkedlifedata.com/resource/pubmed/chemical/Antimetabolites, Antineoplastic,
http://linkedlifedata.com/resource/pubmed/chemical/Cytarabine,
http://linkedlifedata.com/resource/pubmed/chemical/Dexamethasone,
http://linkedlifedata.com/resource/pubmed/chemical/Organoplatinum Compounds,
http://linkedlifedata.com/resource/pubmed/chemical/oxaliplatin,
http://linkedlifedata.com/resource/pubmed/chemical/rituximab
|
|
pubmed:status |
MEDLINE
|
|
pubmed:issn |
0030-2414
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
69
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
499-502
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:16424679-Aged,
pubmed-meshheading:16424679-Aged, 80 and over,
pubmed-meshheading:16424679-Antibodies, Monoclonal,
pubmed-meshheading:16424679-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:16424679-Antimetabolites, Antineoplastic,
pubmed-meshheading:16424679-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:16424679-Cytarabine,
pubmed-meshheading:16424679-Dexamethasone,
pubmed-meshheading:16424679-Female,
pubmed-meshheading:16424679-Humans,
pubmed-meshheading:16424679-Lymphoma, B-Cell,
pubmed-meshheading:16424679-Lymphoma, Large B-Cell, Diffuse,
pubmed-meshheading:16424679-Male,
pubmed-meshheading:16424679-Middle Aged,
pubmed-meshheading:16424679-Organoplatinum Compounds,
pubmed-meshheading:16424679-Retrospective Studies,
pubmed-meshheading:16424679-Survival Analysis,
pubmed-meshheading:16424679-Treatment Outcome
|
|
pubmed:year |
2005
|
|
pubmed:articleTitle |
Rituximab, Ara-C, dexamethasone and oxaliplatin is safe and active in heavily pretreated patients with diffuse large B-cell lymphoma.
|
|
pubmed:affiliation |
Division of Bone Marrow Transplantation, Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria.
|
|
pubmed:publicationType |
Journal Article
|
